Abstract
Bronchopulmonary dysplasia (BPD) is associated with significant short- and long-term morbidity in preterm infants, and it can be prevented in some infants with vitamin A prophylaxis. Vitamin A, once widely used in neonatal intensive care, was scarce for the last few years, but has become available again at a much higher price, leading to dilemmas about its routine use. In this review we discuss experimental, clinical and socioeconomic evidence related to BPD, and provide a framework for clinicians and policy-makers to evaluate the value of vitamin A treatment and make decisions about its use for prevention of BPD.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial
BMC Pediatrics Open Access 16 December 2017
-
Linking bronchopulmonary dysplasia to adult chronic lung diseases: role of WNT signaling
Molecular and Cellular Pediatrics Open Access 07 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maitre NL, Ballard RA, Ellenberg JH, Davis SD, Greenberg JM, Hamvas A et al. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol 2015; 35 (5): 313–321.
Northway WH Jr . Rosan RC, Porter DY . Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276 (7): 357–368.
Jobe AJ . The new BPD: an arrest of lung development. Pediatr Res 1999; 46 (6): 641–643.
Jobe AH, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163 (7): 1723–1729.
Vogel ER, Britt RD Jr . Trinidad MC, Faksh A, Martin RJ, MacFarlane PM et al. Perinatal oxygen in the developing lung. Can J Physiol Pharmacol 2015; 93 (2): 119–127.
Couroucli XI, Liang YH, Jiang W, Wang L, Barrios R, Yang P et al. Prenatal administration of the cytochrome P4501A inducer, Beta-naphthoflavone (BNF), attenuates hyperoxic lung injury in newborn mice: implications for bronchopulmonary dysplasia (BPD) in premature infants. Toxicol Appl Pharmacol 2011; 256 (2): 83–94.
Xia H, Ren X, Bolte CS, Ustiyan V, Zhang Y, Shah TA et al. Foxm1 regulates resolution of hyperoxic lung injury in newborns. Am J Respir Cell Mol Biol 2015; 52 (5): 611–621.
Zhang S, Patel A, Chu C, Jiang W, Wang L, Welty SE et al. Aryl hydrocarbon receptor is necessary to protect fetal human pulmonary microvascular endothelial cells against hyperoxic injury: mechanistic roles of antioxidant enzymes and RelB. Toxicol Appl Pharmacol 2015; 286 (2): 92–101.
Bose CL, Dammann CE, Laughon MM . Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed 2008; 93 (6): F455–F461.
Hair AB, Hawthorne KM, Chetta KE, Abrams SA . Human milk feeding supports adequate growth in infants ⩽1250 grams birth weight. BMC Res Notes 2013; 6: 459.
Ambalavanan N, Cotten CM, Page GP, Carlo WA, Murray JC, Bhattacharya S et al. Integrated genomic analyses in bronchopulmonary dysplasia. J Pediatr 2015; 166 (3): 531–537.e513.
Hagood JS . Beyond the genome: epigenetic mechanisms in lung remodeling. Physiology 2014; 29 (3): 177–185.
Cuna A, Halloran B, Faye-Petersen O, Kelly D, Crossman DK, Cui X et al. Alterations in gene expression and DNA methylation during murine and human lung alveolar septation. Am J Respir Cell Mol Biol 2014; 53 (1): 60–73.
Mehta P, Berger J, Bucholz E, Bhandari V . Factors affecting nasal intermittent positive pressure ventilation failure and impact on bronchopulmonary dysplasia in neonates. J Perinatol 2014; 34 (10): 754–760.
Lingappan K, Jiang W, Wang L, Couroucli XI, Moorthy B . Sex-specific differences in hyperoxic lung injury in mice: role of cytochrome P450 (CYP)1 A. Toxicology 2015; 331: 14–23.
Gritz EC, Bhandari V . The human neonatal gut microbiome: a brief review. Front Pediatr 2015; 3: 17.
O'Reilly M, Sozo F, Harding R . Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health. Clin Exp Pharmacol Physiol 2013; 40 (11): 765–773.
McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL . Bronchopulmonary dysplasia: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc 2014; 11 (Suppl 3): S146–S153.
Baker CD, Abman SH . Impaired pulmonary vascular development in bronchopulmonary dysplasia. Neonatology 2015; 107 (4): 344–351.
Blaisdell CJ, Weinmann GG . NHLBI viewpoint: lung health and disease prevention research starting in childhood. Pediatr Pulmonol 2015; 50 (6): 604–606.
Bolton CE, Bush A, Hurst JR, Kotecha S, McGarvey L . Lung consequences in adults born prematurely. Thorax 2015; 70 (6): 574–580.
Johnson TJ, Patel AL, Jegier BJ, Engstrom JL, Meier PP . Cost of morbidities in very low birth weight infants. J Pediatr 2013; 162 (2): 243–249.e241.
Greenough A, Alexander J, Boorman J, Chetcuti PA, Cliff I, Lenney W et al. Respiratory morbidity, healthcare utilisation and cost of care at school age related to home oxygen status. Eur J Pediatr 2011; 170 (8): 969–975.
Miller VL, Rice JC, DeVoe M, Fos PJ . An analysis of program and family costs of case managed care for technology-dependent infants with bronchopulmonary dysplasia. J Pediatr Nurs 1998; 13 (4): 244–251.
Landry JS, Croitoru D, Jin Y, Schwartzman K, Benedetti A, Menzies D . Health care utilization by preterm infants with respiratory complications in Quebec. Can Respir J -2012; 19 (4): 255–260.
Sipola-Leppanen M, Vaarasmaki M, Tikanmaki M, Matinolli HM, Miettola S, Hovi P et al. Cardiometabolic risk factors in young adults who were born preterm. Am J Epidemiol 2015; 181 (11): 861–873.
Stocks J, Sonnappa S . Early life influences on the development of chronic obstructive pulmonary disease. Ther Adv Respir Dis 2013; 7 (3): 161–173.
Joss-Moore LA, Lane RH, Albertine KH . Epigenetic contributions to the developmental origins of adult lung disease. Biochem Cell Biol 2015; 93 (2): 119–127.
Beam KS, Aliaga S, Ahlfeld SK, Cohen-Wolkowiez M, Smith PB, Laughon MM . A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. J Perinatol 2014; 34 (9): 705–710.
Viscardi RM . Pharmacological options for BPD prevention: steps for better clinical trial design. J Perinatol 2014; 34 (9): 656–657.
Schmidt B, Roberts R, Millar D, Kirpalani H . Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 2008; 93 (4): 284–287.
Jensen EA, Foglia EE, Schmidt B . Evidence-based pharmacologic therapies for prevention of bronchopulmonary dysplasia: application of the grading of recommendations assessment, development, and evaluation methodology. Clin Perinatol 2015; 42 (4): 755–779.
Sommer A, Vyas KS . A global clinical view on vitamin A and carotenoids. Am J Clin Nutr 2012; 96 (5): 1204S–1206S.
Benbrook DM, Chambon P, Rochette-Egly C, Asson-Batres MA . History of retinoic acid receptors. Subcell Biochem 2014; 70: 1–20.
Napoli JL . Physiological insights into all-trans-retinoic acid biosynthesis. Biochim Biophys Acta 2012; 1821 (1): 152–167.
Ghanta S, Leeman KT, Christou H . An update on pharmacologic approaches to bronchopulmonary dysplasia. Semin Perinatol 2013; 37 (2): 115–123.
Maden M, Hind M . Retinoic acid in alveolar development, maintenance and regeneration. Philos Trans R Soc Lond B Biol Sci 2004; 359 (1445): 799–808.
James ML, Ross AC, Nicola T, Steele C, Ambalavanan N . VARA attenuates hyperoxia-induced impaired alveolar development and lung function in newborn mice. Am J Physiol Lung Cell Mol Physiol 2013; 304 (11): L803–L812.
Gudas LJ . Emerging roles for retinoids in regeneration and differentiation in normal and disease states. Biochim Biophys Acta 2012; 1821 (1): 213–221.
Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C . Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res 2005; 57 (5 Pt 2): 38R–46R.
Madanayake TW, Lindquist IE, Devitt NP, Mudge J, Rowland AM . A transcriptomic approach to elucidate the physiological significance of human cytochrome P450 2S1 in bronchial epithelial cells. BMC Genomics 2013; 14: 833.
Dib H, Chafey P, Clary G, Federici C, Le Gall M, Dwyer J et al. Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition. Proteomics 2012; 12 (15–16): 2547–2555.
Londhe VA, Maisonet TM, Lopez B, Shin BC, Huynh J, Devaskar SU . Retinoic acid rescues alveolar hypoplasia in the calorie-restricted developing rat lung. Am J Respir Cell Mol Biol 2013; 48 (2): 179–187.
Londhe VA, Nolen TL, Das A, Higgins RD, Tyson JE, Oh W et al. Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants. Am J Perinatol 2013; 30 (9): 771–780.
Shenai JP, Chytil F, Stahlman MT . Vitamin A status of neonates with bronchopulmonary dysplasia. Pediatr Res 1985; 19 (2): 185–188.
Shenai JP, Rush MG, Stahlman MT, Chytil F . Vitamin A supplementation and bronchopulmonary dysplasia–revisited. J Pediatr 1992; 121 (3): 399–401.
Mactier H, Weaver LT . Vitamin A and preterm infants: what we know, what we don't know, and what we need to know. Arch Dis Child Fetal Neonatal Ed 2005; 90 (2): F103–F108.
Ambalavanan N, Wu TJ, Tyson JE, Kennedy KA, Roane C, Carlo WA . A comparison of three vitamin A dosing regimens in extremely-low-birth-weight infants. J Pediatr 2003; 142 (6): 656–661.
Shenai JP, Kennedy KA, Chytil F, Stahlman MT . Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987; 111 (2): 269–277.
Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340 (25): 1962–1968.
Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 2005; 115 (3): e249–e254.
Darlow BA, Graham PJ . Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2011; (10): CD000501.
Laughon MM . Vitamin A shortage and risk of bronchopulmonary dysplasia. JAMA Pediatr 2014; 168 (11): 995–996.
Mactier H . Vitamin A for preterm infants; where are we now? Semin Fetal Neonatal Med 2013.
Meyer S, Gortner L, NeoVita ATI . Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology 2014; 105 (3): 182–188.
Darlow BA, Graham PJ . Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007; (4): CD000501.
Milstone AM, Reich NG, Advani S, Yuan G, Bryant K, Coffin SE et al. Catheter dwell time and CLABSIs in neonates with PICCs: a multicenter cohort study. Pediatrics 2013; 132 (6): e1609–e1615.
Fewtrell MS, Edmonds CJ, Isaacs E, Bishop NJ, Lucas A . Aluminium exposure from parenteral nutrition in preterm infants and later health outcomes during childhood and adolescence. Proc Nutr Soc 2011; 70 (3): 299–304.
Tolia VN, Murthy K, McKinley PS, Bennett MM, Clark RH . The effect of the national shortage of vitamin A on death or chronic lung disease in extremely low-birth-weight infants. JAMA Pediatr 2014; 168 (11): 1039–1044.
Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10): 1039–1051.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Couroucli, X., Placencia, J., Cates, L. et al. Should we still use vitamin A to prevent bronchopulmonary dysplasia?. J Perinatol 36, 581–585 (2016). https://doi.org/10.1038/jp.2016.76
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2016.76
This article is cited by
-
Say no to drugs: wait and watch strategy for medications used in the neonatal intensive care unit (NICU)
World Journal of Pediatrics (2020)
-
Oral vitamin A supplementation in very low birth weight neonates: a randomized controlled trial
European Journal of Pediatrics (2019)
-
“Good things come in small packages”: application of exosome-based therapeutics in neonatal lung injury
Pediatric Research (2018)
-
Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial
BMC Pediatrics (2017)
-
Linking bronchopulmonary dysplasia to adult chronic lung diseases: role of WNT signaling
Molecular and Cellular Pediatrics (2016)